Resverlogix (TSE:RVX) Posts Earnings Results

Resverlogix (TSE:RVX) announced its quarterly earnings data on Friday. The biotechnology company reported C$0.01 EPS for the quarter, FiscalAI reports.

Resverlogix Price Performance

Shares of TSE:RVX opened at C$0.10 on Friday. Resverlogix has a 1-year low of C$0.04 and a 1-year high of C$0.30. The firm has a market capitalization of C$30.04 million, a PE ratio of -3.17 and a beta of 0.72. The business’s 50 day moving average is C$0.11 and its 200-day moving average is C$0.10. The company has a current ratio of 0.04, a quick ratio of 0.04 and a debt-to-equity ratio of -81.94.

About Resverlogix

Resverlogix Corp clinical-stage biotechnology company. The company is developing an advanced epigenetic drug called apabetalone for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative diseases.